Characterization of Treatment Resistance and Viral Kinetics in the Setting of Single-Active Versus Dual-Active Monoclonal Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2
The Journal of Infectious Diseases · 2024
DOI: 10.1093/infdis/jiae192 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Manish C Choudhary und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, Viral Load, Antibodies, Monoclonal, Humanized, COVID-19 Drug Treatment. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, NIH HHS.
Abstract (Originalsprache)
Background
Monoclonal antibodies (mAbs) represent a crucial antiviral strategy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but it is unclear whether combination mAbs offer a benefit over single-active mAb treatment. Amubarvimab and romlusevimab significantly reduced the risk of hospitalizations or death in the ACTIV-2/A5401 trial. Certain SARS-CoV-2 variants are intrinsically resistant against romlusevimab, leading to only single-active mAb therapy with amubarvimab in these variants. We evaluated virologic outcomes in individuals treated with single- versus dual-active mAbs.
Methods
Participants were nonhospitalized adults at higher risk of clinical progression randomized to amubarvimab plus romlusevimab or placebo. Quantitative SARS-CoV-2 RNA levels and targeted S-gene next-generation sequencing was performed on anterior nasal samples. We compared viral load kinetics and resistance emergence between individuals treated with effective single- versus dual-active mAbs depending on the infecting variant.
Results
Study participants receiving single- or dual-active mAbs had similar demographics, baseline nasal viral load, symptom score, and symptom duration. Compared with single-active mAb treatment, treatment with dual-active mAbs led to faster viral load decline at study days 3 (P < .001) and 7 (P < .01). Treatment-emergent resistance mutations were more likely to be detected after amubarvimab plus romlusevimab treatment than with placebo (2.6% vs 0%; P < .001) and were more frequently detected in the setting of single-active compared with dual-active mAb treatment (7.3% vs 1.1%; P < .01). Single-active and dual-active mAb treatment resulted in similar decrease in rates of hospitalizations or death.
Conclusions
Compared with single-active mAb therapy, dual-active mAbs led to similar clinical outcomes but significantly faster viral load decline and a lower risk of emergent resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
- Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
- Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
- Department of Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.
- Brii Biosciences, Durham, North Carolina, USA.
ORCID-Profile: Mark J Giganti, Carlee Moser, Alexander L Greninger, Jonathan Z Li
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
- NIH HHS
- National Institutes of Health
Zitieren
APA
Choudhary, M. C., Deo, R., Evering, T. H., Chew, K. W., Giganti, M. J., Moser, C., Ritz, J., Regan, J., Flynn, J. P., Crain, C. R., Wohl, D. A., Currier, J. S., Eron, J. J., Margolis, D., Zhu, Q., Zhon, L., Ya, L., Greninger, A. L., Hughes, M. D., …, & Li, J. Z. (2024). Characterization of Treatment Resistance and Viral Kinetics in the Setting of Single-Active Versus Dual-Active Monoclonal Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae192
Vancouver
Choudhary MC, Deo R, Evering TH, Chew KW, Giganti MJ, Moser C, et al. Characterization of Treatment Resistance and Viral Kinetics in the Setting of Single-Active Versus Dual-Active Monoclonal Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiae192
BibTeX
@article{Choudhary2024,
author = {Choudhary, Manish C and Deo, Rinki and Evering, Teresa H and Chew, Kara W and Giganti, Mark J and Moser, Carlee and Ritz, Justin and Regan, James and Flynn, James P and Crain, Charles R and Wohl, David Alain and Currier, Judith S and Eron, Joseph J and Margolis, David and Zhu, Qing and Zhon, Lijie and Ya, Li and Greninger, Alexander L and Hughes, Michael D and Smith, Davey and Daar, Eric S and Li, Jonathan Z},
title = {Characterization of Treatment Resistance and Viral Kinetics in the Setting of Single-Active Versus Dual-Active Monoclonal Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2},
journal = {The Journal of Infectious Diseases},
year = {2024},
doi = {10.1093/infdis/jiae192}
}
EUVIMED